Open AccessHydroxyapatite/nifuroxazide conjugate: Characterization, drug release and antimicrobial activity
Author(s) -
Željko Radovanović,
Katarina Mihajlovski,
Lidija Radovanović,
Djordje Janaćković,
Rada Petrović
Publication year - 2021
Publication title -
journal of the serbian chemical society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.227
H-Index - 45
eISSN - 1820-7421
pISSN - 0352-5139
DOI - 10.2298/jsc210420040r
Subject(s) - conjugate , chemistry , antimicrobial , biocompatibility , drug , solubility , escherichia coli , nuclear chemistry , pharmacology , biochemistry , organic chemistry , medicine , mathematical analysis , mathematics , gene
Synthetic hydroxyapatite (Ca10(PO4)6(OH)2, HAp) is very similar to the inorganic part of the bones and teeth of mammals. It is a well-known biomaterial with good biocompatibility, osteoconductivity and bioactivity. Nifuroxazide (C12H9N3O5, NFX) is a broad-spectrum antibacterial drug and poorly soluble in water. In order to increase the solubility of NFX, nano-sized HAp powder and raw NFX drug were mixed giving, as a result, a HAp/NFX conjugate. Characterization of the raw materials and the obtained conjugate confirmed the integration of NFX on the HAp surface. An in vitro study of drug release in simulated stomach acid and intestinal fluid showed a much faster release of NFX from HAp surface than those of the raw drug. The HAp/NFX conjugate showed excellent inhibitory effects against Gram-positive bacterium Staphylococcus aureus, Gram-negative bacterium Escherichia coli and yeast Candida albicans, proving the nano-sized HAp powder as a promising drug carrier.